In recent years, advances in cancer immunology research have led to the development of immune checkpoint inhibitors for anticancer treatments against many types of malignant neoplasms. However, immunological approaches have already achieved great success in the treatment of hematological malignancies, due to their specificity. In this review article, we discuss hematological malignancies from the perspective of cancer immunology, along with the advancement of monoclonal antibodies since the advent of rituximab, and the development of immune checkpoint inhibitors.
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